Abstract
After undergoing arrival processing at one of two commercial feedlots, feeder calves with clinical signs of bovine respiratory disease (BRD) were randomly assigned to receive either tulathromycin (2.4 mg/kg SC) or enrofloxacin (12.5 mg/kg SC). Additional therapy for calves that did not respond to initial treatment followed a prescribed course. Initial treatment with tulathromycin resulted in significantly higher (P = .009 and P = .031 at sites 1 and 2, respectively) therapeutic success (87.9% and 80%, respectively) than did initial treatment with enrofloxacin (70.2% and 62.5%, respectively). Animals treated with tulathromycin also had fewer subsequent treatments and higher weight gains compared with those treated with enrofloxacin.
Publication types
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Animals, Newborn
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / therapeutic use*
-
Bovine Respiratory Disease Complex / drug therapy*
-
Cattle
-
Colorado
-
Disaccharides / administration & dosage
-
Disaccharides / therapeutic use*
-
Enrofloxacin
-
Fluoroquinolones / administration & dosage
-
Fluoroquinolones / therapeutic use*
-
Heterocyclic Compounds / administration & dosage
-
Heterocyclic Compounds / therapeutic use*
-
Injections, Subcutaneous / veterinary
-
Recurrence
-
Texas
-
Treatment Outcome
-
Weight Gain
Substances
-
Anti-Bacterial Agents
-
Disaccharides
-
Fluoroquinolones
-
Heterocyclic Compounds
-
Enrofloxacin
-
tulathromycin